554. Deputy Ken O'Flynn asked the Minister for Health whether the HSE monitored the substitution between nebulised products (details supplied) during the supply shortages affecting these medicines in 2025 and 2026; and the steps taken to ensure continuity of treatment for affected patients. [66545/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Ken O'Flynn under the heading Medicinal Products.
196 questions match, newest first.
555. Deputy Ken O'Flynn asked the Minister for Health the data the HSE holds on patients who were unable to access a reimbursed nebulised bronchodilator during recent supply shortages and who consequently purchased an alternative product privately at their own expense; and, if no such data is held, to state that plainly. [66544/26]
556. Deputy Ken O'Flynn asked the Minister for Health whether the reimbursement of alternative nebulised bronchodilator products during periods of shortage, including under the Discretionary Hardship Arrangements, is applied consistently across all health regions; and to provide the number of such claims processed in the period January to June 2026, by health region. [66543/26]
557. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 774 of 14 May 2026, whether the HSE produces prescribing trend analysis for nebulised bronchodilator medications at health region level; and if so, to provide that analysis for the period January to June 2026 broken down by health region. [66542/26]
755. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, to provide the data on the number of pharmacy reimbursement claims adjusted and the number successfully appealed in each year from 2020 to date (details supplied).; and if she will make a statement on the matter. [51052/26]
756. Deputy Ken O'Flynn asked the Minister for Health whether the Primary Care Reimbursement Service holds a national dataset recording the number of pharmacy reimbursement claims adjusted and the number successfully appealed; and if no such dataset is held, to state this plainly; and if she will make a statement on the matter. [51053/26]
757. Deputy Ken O'Flynn asked the Minister for Health to set out the formal mechanism, if any, by which a pharmacy may appeal a rejected reimbursement claim; the average time to determination; the number and proportion of such appeals upheld in each year from 2020 to date; and if she will make a statement on the matter. [51054/26]
758. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, to reconcile the figures provided in the reply, given that the difference between claims submitted (details supplied); and if she will make a statement on the matter. [51055/26]
759. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, recording "eligibility expired" as the leading reason for pharmacy claim rejection in the years 2020 to 2022, peaking at 30,005 rejections in 2021; the assessment that has been made of the impact on patients dispensed medicines whose eligibility had lapsed at point of dispensing, including whether any such…
764. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, to now provide those figures for each year, or to confirm that no such data is held by the Health Service Executive (details supplied). [51061/26]
765. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, to clarify whether the figure provided for the number of pharmacy reimbursement claims rejected in each year counts unique claims finally refused or counts error events including claims that were subsequently paid; and the reason the combined total of claims approved and claims rejected exceeds the number …
766. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, in which "claim set to pay or already paid" appears among the top five recorded reasons for claim rejection; to provide and the number of pharmacy reimbursement claims that were initially rejected and subsequently paid in each year from 2020 to date, or to confirm that this is not separately recorded [5106…
767. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, whether a formal appeals mechanism exists for rejected pharmacy reimbursement claims; if so, the body responsible for deciding such appeals; and the number of appeals received and the number upheld in each year from 2020 to date. [51064/26]
517. Deputy Ken O'Flynn asked the Minister for Health further to the HSE's confirmation that no national dataset on returned medicines currently exists, whether the national medicines disposal service under CPA25 will record returned medicines as a defined, structured national dataset; to specify the data fields that dataset will capture; and if she will make a statement on the matter. [50611/26]
518. Deputy Ken O'Flynn asked the Minister for Health whether data on the volume, type and cost of medicines returned under the CPA25 disposal service will be published; the frequency of such publication; the date on which the first such report will issue; and if she will make a statement on the matter. [50612/26]
519. Deputy Ken O'Flynn asked the Minister for Health the confirmed commencement date of the national medicines disposal service under CPA25, given the HSE's statement that the service is due to commence "over the summer" in 2026; and if she will make a statement on the matter. [50613/26]
520. Deputy Ken O'Flynn asked the Minister for Health whether a baseline estimate of the annual cost of unused, expired or otherwise wasted medicines will be established at the commencement of the CPA25 disposal service; the methodology to be applied; and if she will make a statement on the matter. [50614/26]
521. Deputy Ken O'Flynn asked the Minister for Health whether waste-reduction targets will be set on foot of the data collected under the CPA25 disposal service; the office responsible for owning and governing that dataset; whether that dataset features on any HSE risk register or audit plan; and if she will make a statement on the matter. [50615/26]
789. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2547 of 9 June 2026, the number of the 12,899 respiratory medicine claims rejected under the PCRS between 2023 and 2026 to date, that remain unpaid following resubmission; the breakdown of this unrecovered figure, by year and, by rejection reason; the steps her Department and the HSE are taking to address the volume of rejecti…
2049. Deputy Ken O'Flynn asked the Minister for Health whether the forthcoming national medicines disposal programme will include medicine-level cataloguing, reimbursement category tracking, estimated retail value assessment, or analysis of prescribing source; and if she will make a statement on the matter. [42486/26]
2050. Deputy Ken O'Flynn asked the Minister for Health whether her Department or HSE has conducted any international benchmarking regarding medicines waste reduction strategies in comparable EU jurisdictions; and if so, to provide details. [42487/26]
2051. Deputy Ken O'Flynn asked the Minister for Health whether any estimate exists of medicines dispensed under State-funded schemes but not consumed due to non-adherence, therapy change, duplication, early discontinuation, death, hospital admission, or over-prescribing; and if she will make a statement on the matter. [42488/26]
2052. Deputy Ken O'Flynn asked the Minister for Health whether the HSE intends to publish annual reports arising from the new national medicines disposal programme, including estimated financial value and environmental impact of returned medicines. [42489/26]
2327. Deputy Ken O'Flynn asked the Minister for Health whether any review, analysis, assessment, briefing, report, business case, internal examination or other evaluation has been undertaken since 1 January 2024 regarding the drivers of variation in reimbursement costs for salbutamol nebule products under the General Medical Services Scheme; if so, to provide the date, author, purpose and principal findings of each s…
2414. Deputy Ken O'Flynn asked the Minister for Health to outline the governance arrangements governing reimbursement rule changes, claim validation criteria, claim rejection criteria and reference pricing decisions within the Primary Care Reimbursement Service, including the decision-making authorities involved, review mechanisms and oversight structures. [44052/26]